Skip to main content
. 2021 Feb 3;4(2):e2036330. doi: 10.1001/jamanetworkopen.2020.36330

Table 3. Cox Proportional Hazards Regression Analysis of the Association of Local and Systemic Recurrence With Patient and Surgical Factorsa.

Characteristic Hazard ratio (95% CI)
Local recurrence, univariate Systemic recurrence
Univariate Multivariate
Body mass index
Underweight or normal 1 [Reference] 1 [Reference] NA
Overweight 0.96 (0.38-2.45) 0.99 (0.48-2.04) NA
Obese 0.41 (0.09-1.86) 0.59 (0.33-1.05) NA
Sex
Female 1 [Reference] 1 [Reference] NA
Male 1.62 (0.85-3.07) 0.94 (0.59-1.47) NA
Neoadjuvant therapy
No 1 [Reference] 1 [Reference] 1 [Reference]
Yes 0.75 (0.31-1.83) 1.99 (1.27-3.13)b 1.70 (0.90-3.21)
AJCC stage (clinical)
I 1 [Reference] 1 [Reference] 1 [Reference]
II 0.60 (0.36-1.01) 1.35 (0.73-2.49) 0.72 (0.34-1.55)
III 1.42 (0.83-2.44) 2.30 (1.31-4.03)b 1.17 (0.46-2.98)
IV 1.26 (0.14-10.99) NAc NA
Tumor height 0.92 (0.76-1.12) 1.03 (0.93-1.14) NA
Quality of mesorectum
Incomplete 1 [Reference] 1 [Reference] NA
Complete 0.63 (0.08-5.06) 0.49 (0.13-1.76) NA
CRM
Negative 1 [Reference] 1 [Reference] 1 [Reference]
Positive 4.19 (2.86-6.15)b 4.00 (2.22-7.19)b 2.95 (1.26-6.91)b
DRM
Negative 1 [Reference] 1 [Reference] 1 [Reference]
Positive NAd 4.88 (1.55-15.33) 3.37 (0.72-15.74)

Abbreviations: AJCC, American Joint Committee on Cancer; CRM, circumferential radial margin; DRM, distal resection margin; NA, not applicable.

a

Both models were clustered by site, and the multivariable model was adjusted for neoadjuvant therapy, stage, CRM, and DRM.

b

Significant association.

c

Patients with disease stage IV were removed before data were analyzed.

d

A reliable estimate could not be derived owing to a lack of cases.